scispace - formally typeset
L

Laurie A. Kopin

Researcher at University of Rochester

Publications -  9
Citations -  1468

Laurie A. Kopin is an academic researcher from University of Rochester. The author has contributed to research in topics: Population & Risk factor. The author has an hindex of 7, co-authored 9 publications receiving 1297 citations. Previous affiliations of Laurie A. Kopin include University of Rochester Medical Center.

Papers
More filters
Journal ArticleDOI

The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials

TL;DR: Metformin, in combination with lifestyle modification and OC, reduces central adiposity, reduces total testosterone, and increases HDL, but does not enhance overall weight reduction in obese adolescents with PCOS.
Journal ArticleDOI

The Effect of Giving Global Coronary Risk Information to Adults: A Systematic Review

TL;DR: This paper performed a systematic evidence review to assess the effect of providing global coronary heart disease risk information to adults and found that global CHD risk information alone or with accompanying education increased the accuracy of perceived risk and probably increased intent to start therapy.
Journal ArticleDOI

In the clinic. Dyslipidemia.

TL;DR: This issue provides a clinical overview of dyslipidemia focusing on prevention, diagnosis, treatment, practice improvement, and patient information.
Journal ArticleDOI

Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.

TL;DR: Niacin extended release/lovastatin was also more effective than atorvastatin and simvASTatin monotherapies in reducing small, dense low- density lipoprotein particles and improving low-density lipop protein phenotype pattern at relative starting doses, and was more effective in increasing the proportion of high-densitylipoprotein in the potentially cardioprotective 2b subclass at all doses.